When you drink coffee or other caffeinated beverages, caffeine blocks the receptors in your brain that normally absorb ...

Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

We have been exploring the potential of the neuromodulator, adenosine, to reduce excessive dopamine signaling that contributes to the development and persistence of psychostimulant abuse. Dopamine’s ...

Consuming over 600mg of caffeine daily ( the equivalent of six mugs of brewed coffee) may cause anxiety, insomnia, agitation, ...

A recent study by researchers at the University of Florence and collaborators has demonstrated the efficacy of MRS-3997, a dual adenosine A2A/A2B receptor agonist, in reducing brain damage and ...

The reaction product is adenosine diphosphate (ADP), and the phosphate group either ends up as orthophosphate (HPO 4) or attached to another molecule (e.g. an alcohol). Even more energy can be ...

More than two years after acquiring Tarus Therapeutics, Portage Biotech is relaunching Tarus’ adenosine receptor antagonists in a standalone company helmed by a familiar leader. The offshoot ...

The activation of the adenosine A2A receptor, which is mediated by the inhibition of adenosine A1 receptor, has been associated with depression-like behavior and anhedonia. High levels of cortisol, ...